0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > FKBP12

FKBP12

Brief Information

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKCI2,Tacrolimus Binding Protein 1A,FKBP12C,FK506 Binding Protein 1A, 12kDa,12 KDa FK506-Binding Protein,Immunophilin FKBP12,12 KDa FKBP,Rotamase,FKBP Prolyl Isomerase 1A,FKBP1,FKBP12,FKBP-12,PPIase FKBP1A,FK506-binding protein 1A,Calstabin-1,FKBP-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
FKA-H5122 Human Human FKBP12 / FKBP1A Protein, His Tag
FKA-H5122-structure
FKA-H5122-sds
ACRO Quality

Synonym Name

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

Background

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tacrolimus Hydrate LCP-Tacro; FR-900506; L-679934; FK-506MR; FK-506E; FK-506; MR-4; RTU-007 Approved Astellas Pharma Inc Protopy, Graceptor (as hydrate), Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, 普乐可复, Advagraf, Envarsus, Modigraf, Astagraf XL, TacroBell Japan Rejection of organ transplantation; Myasthenia Gravis; Conjunctivitis, Allergic; Lupus Nephritis; Coronary Restenosis; Dermatitis, Atopic; Arthritis, Rheumatoid; Colitis, Ulcerative Astellas Pharma Inc 1993-01-01 Renal Insufficiency, Chronic; Brain Death; Psoriasis; Amputation, Traumatic; Conjunctivitis, Allergic; Pulmonary Arterial Hypertension; Asthma; Surgical Wound Infection; Burns; Colitis, Ulcerative; Infertility, Female; Rejection in heart transplantation; Conjunctivitis; Wounds and Injuries; Nephrotic Syndrome; Keratoconjunctivitis; Coronary Restenosis; Ocular inflammation; Dermatitis, Atopic; Edema; Crohn Disease; Vitiligo; Peripheral Nerve Injuries; Encephalitis; Renal Insufficiency; Polymyositis; Rejection of renal transplantation; Liver Failure; Myasthenia Gravis; Medication Adherence; Reperfusion Injury; Genital Diseases, Male; Bone marrow transplant rejection; Rejection of liver transplantation; Rejection of lung transplantation; Glomerulonephritis, IGA; Keratoconjunctivitis Sicca; Dermatomyositis; Primary Graft Dysfunction; Keratoplasty rejection; Kidney Diseases; Lupus Erythematosus, Cutaneous; Graft vs Host Disease; Arthritis, Rheumatoid; Rejection of organ transplantation; Dry Eye Syndromes; Lung Di Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Plerixafor/Tacrolimus Hydrate MRG-001(MedRegen); AMD3100+FK506 Phase 2 Clinical MedRegen LLC Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries Details
Rimiducid AP-1903 Phase 2 Clinical Ariad Pharmaceuticals Inc, Bellicum Pharmaceuticals Inc Neuroblastoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Metabolic Diseases; Osteopetrosis; Osteosarcoma; Sarcoma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Anemia, Sickle Cell; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Congenital Bone Marrow Failure Syndromes; Melanoma; Thalassemia; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Leukemia; Hematologic Neoplasms; Lymphoma, B-Cell; Solid tumours; Immunoproliferative Disorders; Leukemia, Lymphoid; Lymphatic Diseases; Primary Immunodeficiency Diseases; Anemia, Diamond-Blackfan; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hemoglobinopathies; Fanconi Anemia; Neoplasms; Immune System Diseases Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken